Functional Multidrug Resistance Protein (MRP1) Lacking the N-terminal Transmembrane Domain*
- Éva Bakos‡,§¶,
- Raymond Evers¶,‖,
- Gergely Szakács§,
- Gábor E. Tusnády‡,
- Ervin Welker‡,§,
- Katalin Szabó‡,§,
- Marcel de Haas‖,
- Liesbeth van Deemter‖,
- Piet Borst‖,
- András Váradi‡ and
- Balázs Sarkadi§**
- From the ‡Institute of Enzymology, Biological Research Center, Hungarian Academy of Sciences and §National Institute of Haematology and Immunology, Research Group of the Hungarian Academy of Sciences, H-1113 Budapest, Hungary and ‖The Netherlands Cancer Institute, Division of Molecular Biology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
Abstract
The human multidrug resistance protein (MRP1) causes drug resistance by extruding drugs from tumor cells. In addition to an MDR-like core, MRP1 contains an N-terminal membrane-bound region (TMD0) connected to the core by a cytoplasmic linker (L0). We have studied truncated MRP1 versions containing either the MDR-like core alone or the core plus linker L0, produced in the baculovirus-insect (Sf9) cell system. Their function was examined in isolated membrane vesicles. Full-length MRP1 showed ATP-dependent, vanadate-sensitive accumulation of leukotriene C4 and N-ethylmaleimide glutathione. In addition, leukotriene C4-stimulated, vanadate-dependent nucleotide occlusion was detected. The MDR-like core was virtually inactive. Co-expression of the core with the N-terminal region including L0 fully restored MRP1 function. Unexpectedly, a truncated MRP1 mutant lacking the entire TMD0 region but still containing L0 behaved like wild-type MRP1 in vesicle uptake and nucleotide trapping experiments. We also expressed the MRP1 constructs in polarized canine kidney derived MDCKII cells. Like wild-type MRP1, the MRP1 protein without the TMD0 region was routed to the lateral plasma membrane and transported dinitrophenyl glutathione and daunorubicin. The TMD0L0 and the MRP1 minus TMD0L0 remained in an intracellular compartment. Taken together, these experiments strongly suggest that the TMD0 region is neither required for the transport function of MRP1 nor for its proper routing to the plasma membrane.
Footnotes
-
↵* This work has been supported by Dutch Cancer Society Research Grant NKI 98-1794 (to P. B.), an NWO-OTKA grant (to P. B. and B. S.), and in Budapest by grants from COST, OMFB, OTKA (F23662, T22072, T17602, T6348), FKFP, and ETT.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
↵¶ These authors contributed equally to this work.
-
↵** A recipient of a Howard Hughes International Scholarship. To whom correspondence should be addressed: National Institute of Haematology and Immunology, 1113 Budapest, Daróczi u. 24, Hungary. Tel./Fax: 36-1-372-4353; E-mail: B.Sarkadi{at}ohvi.hu.
- MDR1 Pgp
- human multidrug transporter P-glycoprotein
- ABC
- ATP binding cassette
- DNP-GS
- dinitrophenyl S-glutathione
- GSH
- reduced glutathione
- GSSG
- oxidized glutathione
- ECL
- enhanced chemiluminescence
- LTC4
- leukotriene C4
- MDCK
- Madin-Darby canine kidney
- cMOAT
- canalicular multispecific organic anion transporter
- mAb
- monoclonal antibody
- MRP
- human multidrug resistance (-associated) protein
- NEM-GS
- N-ethylmaleimideS-glutathione
- Sf9 cells
- Spodoptera frugiperda ovarian cells
- TMD
- transmembrane domain
- MOPS
- 4-morpholinepropanesulfonic acid.
- Received August 10, 1998.
- Revision received September 8, 1998.
- The American Society for Biochemistry and Molecular Biology, Inc.











